Literature DB >> 21501598

The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.

Erik De Clercq1.   

Abstract

The use of the acyclic nucleoside phosphonates, starting with (S)-HPMPA as the prototype, yielded three clinically approved antiviral drugs, cidofovir for the treatment of CMV retinitis in AIDS patients, adefovir dipivoxil for the treatment of chronic hepatitis B and tenofovir disoproxil fumarate for the treatment of HIV infections (AIDS) and HBV infections. This era has now grown to many more acyclic (and cyclic) nucleoside phosphonates (such as the "open ring" DAPy and Fd4A phosphonates) and alkoxyalkyl and phosphonoamidate prodrugs thereof, as well as new clinical applications, including new drug combination regimens for the treatment of AIDS, the chemoprophylaxis of HIV infections, and the anticancer potential against some malignant disorders.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21501598     DOI： 10.1016/j.bcp.2011.03.027

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


  21 in total

1.  Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.

Authors:  Natacha Coen; Sophie Duraffour; Lieve Naesens; Marcela Krecmerová; Joost Van den Oord; Robert Snoeck; Graciela Andrei
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  Pre-steady state kinetic analysis of cyclobutyl derivatives of 2'-deoxyadenosine 5'-triphosphate as inhibitors of HIV-1 reverse transcriptase.

Authors:  Jiae Kim; Ligong Wang; Yongfeng Li; Kimberlynne D Becnel; Kathleen M Frey; Scott J Garforth; Vinayaka R Prasad; Raymond F Schinazi; Dennis C Liotta; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2012-04-24       Impact factor: 2.823

Review 3.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 4.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Suppression of Adenovirus Replication by Cardiotonic Steroids.

Authors:  Filomena Grosso; Peter Stoilov; Clifford Lingwood; Martha Brown; Alan Cochrane
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

6.  Effective Prophylactic Therapy for Exposure to Monkey B Virus (Macacine alphaherpesvirus 1).

Authors:  Lara K Maxwell; Darla H Black; George E Wright; Melanie A Breshears; Richard Eberle
Journal:  Comp Med       Date:  2019-12-06       Impact factor: 1.565

Review 7.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

Review 8.  An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Authors:  Erik De Clercq
Journal:  Acta Pharm Sin B       Date:  2015-11-02       Impact factor: 11.413

9.  Transdermal delivery and cutaneous targeting of antivirals using a penetration enhancer and lysolipid prodrugs.

Authors:  Denisa Diblíková; Monika Kopečná; Barbora Školová; Marcela Krečmerová; Jaroslav Roh; Alexandr Hrabálek; Kateřina Vávrová
Journal:  Pharm Res       Date:  2013-11-22       Impact factor: 4.580

10.  Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1.

Authors:  Dimitri Topalis; Tatiane C Nogueira; Tim De Schutter; Chahrazade El Amri; Marcela Krečmerová; Lieve Naesens; Jan Balzarini; Graciela Andrei; Robert Snoeck
Journal:  Oncotarget       Date:  2016-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.